Ann: Director appointments, page-10

Hi Sisu & All,

Just in relation to the discussion on CSL recently, & never saying never - CSL are looking to acquire Vifor Pharma, which is a global company based in Switzerland that specialises in cardio-renal products.

If you remember back always, Janssen have a deal with Vifor to market Invokana (Canafliglozin) in the USA following the approval for DKD/CKD indication from the FDA. Obviously this is the drug that was trialled in the CREDENCE & CANVAS studies, which is the collaboration study between PIQ & Janssen.

https://www.copyright link/companies/healthcare-and-fitness/csl-in-talks-to-buy-10b-swiss-based-vifor-pharma-group-20211202-p59ech?utm_medium=social&utm_campaign=nc&utm_source=Twitter#Echobox=1638430529

So yes it does look like CSL are very interested in increasing their kidney disease assets.